We are live on ! Find out more
CA

Continuum Advisory Portfolio holdings

AUM $1.04B
1-Year Est. Return 21.13%
This Fund
S&P 500
This Quarter Est. Return
+9.05%
1 Year Est. Return
+21.13%
3 Year Est. Return
+59.21%
5 Year Est. Return
+68.09%
10 Year Est. Return
AUM
$831M
AUM Growth
+$54.3M
Cap. Flow
-$782K
Cap. Flow %
-0.09%
Top 10 Hldgs %
27.48%
Holding
1,660
New
4
Increased
253
Reduced
141
Closed
1,237

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$4.49M
2
CRM icon
Salesforce
CRM
+$4.36M
3
NEM icon
Newmont
NEM
+$4.31M
4
ULTA icon
Ulta Beauty
ULTA
+$4.31M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.19M

Sector Composition

Rank Sector Weight
1 Technology 12.24%
2 Financials 5.07%
3 Healthcare 5.06%
4 Consumer Discretionary 3.63%
5 Communication Services 3.04%

Similar funds

Continuum Advisory's Q2 2025 Portfolio in Review

As of Q2 2025, Continuum Advisory held 1,660 positions worth $831M, up 7% from $776M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Continuum Advisory's Q2 2025 filing shows 4 new, 253 increased, 141 reduced and 1,237 closed positions. Its largest new stake was Ulta Beauty: 10,430 shares worth $4.88M. The largest sale was Berkshire Hathaway Class A, an estimated $6.09M.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

  • Continuum Advisory's largest Q2 2025 buy was Ulta Beauty: 10,430 shares worth $4.88M.
  • Continuum Advisory added most to CVS Health in Q2 2025, an estimated $4.49M increase.
  • Continuum Advisory's biggest Q2 2025 reduction was Berkshire Hathaway Class A, cutting an estimated $6.09M.
  • Continuum Advisory fully exited Hartford Financial Services in Q2 2025, selling an estimated $4.63M.
  • Continuum Advisory's ten largest holdings make up 27% of its $831M portfolio in Q2 2025.
  • Continuum Advisory opened 4 new positions and closed 1,237 in Q2 2025.
  • Continuum Advisory's portfolio value rose 7% quarter-over-quarter to $831M.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.